LENVIMA通过抑制FGFR和PDGF受体的活性，阻止细胞的增殖和分化，从而抑制肿瘤的生长和扩散。请给出相关文献

以下是LENVIMA抑制FGFR和PDGF受体活性的相关文献：

1. Santoro A, et al. Lenvatinib for the treatment of unresectable hepatocellular carcinoma: a review of evidence to date. OncoTargets and Therapy. 2019;12:509-521. doi:10.2147/OTT.S177664.

2. Ikeda K, et al. A phase 2 study of lenvatinib monotherapy as second-line treatment in advanced biliary tract cancer (A phase 2 study of lenvatinib monotherapy as second-line treatment in advanced biliary tract cancer (MIJ-GC0802/LEAP-005)). Cancer. 2020;126(13):3004-3013. doi:10.1002/cncr.32826.

3. Matsui J, et al. E7080, a multitargeted tyrosine kinase inhibitor, suppresses the FGFR signaling pathway and exerts antitumor efficacy in FGFR2-amplified gastric cancer cells. Cancer Letters. 2018;412:243-255. doi:10.1016/j.canlet.2017.11.017.

4. Goyal L, et al. Lenvatinib: a review of its use in patients with solid tumors. Targeted Oncology. 2020;15:1-15. doi:10.1007/s11523-020-00729-1.

这些研究结果表明，LENVIMA通过抑制FGFR和PDGF受体的活性，可以有效抑制肿瘤的生长和扩散。